Combined Detection of Mean Platelet Volume and Immunoglobins as a Strategy for the Diagnosis of Systemic Lupus Erythematosus

Source:
By:Changzhi Xu

DOI: https://doi.org/10.30564/jams.v2i4.1228

Abstract:

Objective:To explore the possibility of diagnosing and monitoring patients with systemic lupus erythematosus (SLE) using the combination of mean platelet volume (MPV) and routine immunoglobulin test. Method:116 patients with SLE were divided into 3 groups according to their clinical characteristics, including 29 patients with renal impairment, 44 cases of active stage and 43 cases of inactive patients. 40 healthy subjects were randomly selected as controls. Subjects were tested for routine blood test and plasma Immunoglobins, such as IgG, IgA, IgM, C3, C4, CH50, CRP. The results were analyzed and the characteristics of each group of subjects were determined, the correlation between test results and diagnosis were studied. Result: In comparison to the control group, the serum level of MPV, C3 and C4 were decreased (P<0.05), and C reactive protein level was elevated (P<0.001) in the three groups of SLE patients. The IgG level in active and inactive SLE patients was increased (P<0.0001), CH50 level was decreased in patients with inactive SLE (P<0.05), IgA level of active SLE subjects was found to be elevated (P<0.05), IgM in patients with renal impairment was decreased (P<0.05). Other than that, no other significant characteristic were found. Conclusion: The pathogenesis of SLE is a complex process involving multiple factors. The changes of MPV, IgG, IgA, IgM, C3, C4, CH50 and CRP in SLE patients are characteristic parameters. The combination of the above indicators can help to determine the diagnosis and staging of SLE. The timely diagnosis and treatment of SLE patients has important clinical significance in protecting the organ function of SLE patients and improving the prognosis.

References:

[1] RHEWEY，MANZISM，DYERAR，et al． Differences insubclinical Cardiovascular disease between African American and Caucasian women insystemic lupus erythematosus［J］． Transl Res，2009，153( 2) : 51－53． [2]Hochberb M C. Upadating the American College of Rheumatolgy Revised Criteria for the Classification of Systemic Lupuserythermatosus [J].Arthritis Rheum,1997,40(9):17-25. [3]Hiemann R，Buttner T，Krieger T，et al. Challenge of Automated Sreening and Differentiation of Nor Organ Specific Autoantibodies on HEP2 Cell[J]. Autoimmun Rev,2009,9:17-22. [4]Hepburn AL,Narat S,Mason JC. The management of peripheral blood cytopenias in systemic lupus erythematosus[J]. Rheumatology (Oxford), 2010,49(12):2243-2254. [5]Ponsestel G J, Andreoli L, Scanzi F, et al. The antiphospholipid syndrome in patients with systemic lupus erythematosus.[J]. Journal of Autoimmunity, 2017: 10-20. [6]Schmoeller D, Picarelli M M, Munhoz T P, et al. Mean Platelet Volume and Immature Platelet Fraction in Autoimmune Disorders.[J]. Frontiers of Medicine in China, 2017: 146-146. [7]Martinez R, Rodriguezbayona B, Anez G A, et al. Clinical relevance of circulating anti‐ENA and anti‐dsDNA secreting cells from SLE patients and their dependence on STAT‐3 activation[J]. European Journal of Immunology, 2017, 47(7): 1211-1219. [8]Troldborg A, Jensen L, Deleuran B, et al. The C3dg Fragment of Complement Is Superior to Conventional C3 as a Diagnostic Biomarker in Systemic Lupus Erythematosus[J]. Frontiers in Immunology, 2018. [9]Sandhu V, Quan M. SLE and Serum Complement: Causative, Concomitant or Coincidental?[J]. The Open Rheumatology Journal, 2017, 11(1): 113-122. [10]Du X, Chen H, Zhuang Y, et al. Medication Adherence in Chinese Patients With Systemic Lupus Erythematosus[J]. Jcr-journal of Clinical Rheumatology, 2018.